Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2019 June;71(3) > Minerva Ginecologica 2019 June;71(3):196-206

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Ginecologica 2019 June;71(3):196-206

DOI: 10.23736/S0026-4784.19.04409-5

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Fertility preservation in breast cancer patients

Rachael J. RODGERS

School of Women’s and Children’s Health University of New South Wales, Sydney, Australia



Breast cancer is the most commonly diagnosed cancer in women. As long-term survival rates have improved, there has been a concurrent increase in quality of life considerations, of which fertility preservation is of utmost importance. A number of fertility preservation options are available to women diagnosed with breast cancer, including administration of a GnRH agonist during chemotherapy in an attempt to minimize ovarian damage, oocyte or embryo cryopreservation prior to the administration of chemotherapy, in vitro maturation of oocytes or ovarian tissue cryopreservation. The safety of pregnancy after a diagnosis of breast cancer has been confirmed in numerous studies.


KEY WORDS: Breast neoplasms; Fertility; Fertility preservation; Oocyte; Cryopreservation

top of page